Liquid Biopsy for Early Diagnosis of Cancer, Monitoring Cancer, Companion Diagnostics, and Organ Transplant Rejection Monitoring without the Need for Tissue Biopsy
Liquid Biopsy, a non-invasive alternative to tissue biopsy, can help determine cancer treatments by identifying clinically relevant biomarkers.
No need to extract tissue samples
Detailed description for cancer treatment
Liquid biopsy can be used for early diagnosis (screening), recurrence of cancer (monitoring), and anticancer drug effect (companion diagnostics) using Circulating Tumor Cell* (CTC), a cfDNA derived from cancer cells. The cancer cell-derived cfDNA is analyzed through NGS technology and bioinformatics to see if there is a mutation that causes cancer, and whether it can be effective against the anticancer drug. It is a state-of-the-art personalized precision medical service that confirms whether there are cancer cells.*Circulating Tumor Cell (CTC): Cancer cells circulating in blood vessels